Literature DB >> 1705789

Neutralizing determinants of canine herpesvirus as defined by monoclonal antibodies.

X Xuan1, T Horimoto, J A Limcumpao, A Takumi, Y Tohya, E Takahashi, T Mikami.   

Abstract

Monoclonal antibodies (MoAbs) against canine herpesvirus (CHV) were produced to identify the immunogenic proteins of the virus carrying neutralizing determinants. A panel of 24 MoAbs showing neutralizing activities was obtained and tentatively classified into 3 different groups based on their reactivity patterns in immunoblotting analysis. Group I consisting of 10 clones was specific for 145/112 kDa; Group II of 9 clones, for 80 kDa; and Group III of 5 clones, for 41 kDa glycoproteins (gps). Complement-requirement for neutralizing activities of the MoAbs suggests that gp 145/112 and gp 80 elicit mainly complement-requiring and -enhanced neutralizing antibodies, while gp 41 elicits complement-independent ones. In addition, these MoAbs were used in ELISA additivity tests for functional and topographical mapping of epitopes in each of the CHV gp. The results indicated that antigenic reactivities of gp 145/112 and gp 80 were, respectively, localized on at least 5 and 7 overlapping epitopes. On the other hand, 4 epitopes were identified on gp 41.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705789     DOI: 10.1007/bf01319241

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  18 in total

1.  Bovine herpesvirus type 1 gp87 mediates both attachment of virions to susceptible cells and hemagglutination.

Authors:  K Okazaki; E Honda; T Minetoma; T Kumagai
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Demonstration of canine herpesvirus-specific hemagglutination.

Authors:  K Nemoto; T Horimoto; X N Xuan; K Kusanagi; A Takumi; Y Tohya; M Azetaka; E Takahashi; T Mikami
Journal:  Nihon Juigaku Zasshi       Date:  1990-04

3.  Hemagglutinating activity associated with bovine herpesvirus type 1.

Authors:  P Trépanier; C Séguin; Y Bastien; G Boulay; G Lussier; M Trudel
Journal:  Vet Microbiol       Date:  1985-12       Impact factor: 3.293

4.  Mechanisms of neutralization by monoclonal antibodies to different antigenic sites on the bovine herpesvirus type 1 glycoproteins.

Authors:  K Okazaki; E Honda; T Minetoma; T Kumagai
Journal:  Virology       Date:  1986-04-15       Impact factor: 3.616

5.  Neutralization of sensitized virus by purified components of complement.

Authors:  C A Daniels; T Borsos; H J Rapp; R Snyderman; A L Notkins
Journal:  Proc Natl Acad Sci U S A       Date:  1970-03       Impact factor: 11.205

6.  Neutralizing determinants defined by monoclonal antibodies on polypeptides specified by bovine herpesvirus 1.

Authors:  J K Collins; A C Butcher; C A Riegel; V McGrane; C D Blair; Y A Teramoto; S Winston
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

7.  Intracellular localization and epitope mapping of feline herpesvirus type 1 glycoproteins.

Authors:  J A Limcumpao; T Horimoto; E Takahashi; T Mikami
Journal:  Nihon Juigaku Zasshi       Date:  1990-04

8.  Serodiagnosis of canine herpesvirus infection--development of an enzyme-linked immunosorbent assay and its comparison with two improved methods of serum neutralization test.

Authors:  A Takumi; K Kusanagi; K Tuchiya; X N Xuan; M Azetaka; E Takahashi
Journal:  Nihon Juigaku Zasshi       Date:  1990-04

9.  Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90.

Authors:  K A Hussain; C J Issel; K L Schnorr; P M Rwambo; M West; R C Montelaro
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

10.  The immunological relationship between canine herpesvirus and four other herpesviruses.

Authors:  A Manning; A Buchan; G R Skinner; J Durham; H Thompson
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

View more
  1 in total

1.  Glycoprotein-specific immune response in canine herpesvirus infection.

Authors:  X Xuan; T Horimoto; J A Limcumpao; Y Tohya; E Takahashi; T Mikami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.